www.dailypolitical.com ·
Inhibrx Biosciences Nasdaqinbx Posts Quarterly Earnings Results Misses Estimates by 0 47 Eps
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe earnings miss is a company-specific event with no direct commodity or supply-chain impact. The commercial mechanism is limited to a single stock price reaction (1.5% decline) due to an EPS miss. No scarcity, demand spike, or regulatory channel is triggered. The sector is biotech, but the impact is isolated to INBX.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Inhibrx Biosciences (NASDAQ: INBX) reported Q1 2026 EPS loss of $2.15, missing estimates of $1.68 by $0.47.
- Shares fell 1.5% to $116.16 on the earnings miss.
- Market cap is $1.70 billion, debt-to-equity ratio is 12.58.
- Institutional ownership is 82.46%.
- Lead candidate INBRX-109 targets tissue repair and regeneration.
No mid-term impact on the sector; INBRX-109 development continues unaffected.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid